이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ADMA Biologics 배당금

배당금 기준 확인 0/6

ADMA Biologics 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$0.016
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?

May 30

ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

May 13

Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)

Apr 03

ADMA Biologics: On A Roll Entering 2024

Jan 19

Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

Jan 09

ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Jan 09

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Oct 25

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Jun 10

The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

May 12

ADMA Biologics: Strong Growth Is Clearing The Path To Profitability

Aug 21

ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M

Aug 10

ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

Jun 01

ADMA Biologics: A Path To Profits Looks Clear

May 12

ADMA: Pertinent Updates

Apr 18

ADMA Biologics' 2021 Numbers Showed Continued Strong Execution

Mar 29

ADMA Biologics: 2021 Was Tough

Jan 18

ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

Dec 02

ADMA Biologics: Turning A Corner

Nov 20

ADMA: Insiders Showing Their Cards

Nov 02

ADMA Biologics: Recent Significant Developments And Their Implications For The Stock

Aug 22

ADMA Biologics: Feeling Bullish After Encouraging Q2 Earnings Report

Aug 14

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 ADMA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: ADMA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

ADMA Biologics 시장 대비 배당 수익률

ADMA 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (ADMA)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Biotechs)	2.8%
3년 후 애널리스트 예측 (ADMA)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ADMA 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ADMA 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ADMA 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: ADMA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

ADMA Biologics 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?

ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

Giving ADMA Biologics A Well-Deserved 'Booyah'

Forecast to breakeven in 2024

ADMA Biologics, Inc. Revises Earnings Guidance for the Full Year 2024 and 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares

ADMA Biologics, Inc. to Report Q1, 2024 Results on May 09, 2024

ADMA Biologics, Inc., Annual General Meeting, Jun 04, 2024

Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)

Adma Biologics, Inc. Announces FDA Approvals of Extended Room Temperature Storage Conditions for Asceniv & Bivigam

Full year 2023 earnings: EPS misses analyst expectations

ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025

ADMA Biologics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Price target increased by 15% to US$6.88

ADMA Biologics: On A Roll Entering 2024

Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

ADMA Biologics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023, Fiscal Year 2024-2025

ADMA Biologics, Inc. Announces FDA Approval for BIVIGAM in the Pediatric Patient Setting for Those 2 Years of Age and Older

ADMA Biologics, Inc. Receives FDA Approval for Its Tenth Plasma Collection Center, Located in Laurel, MD

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ADMA Biologics, Inc. Updates Financial Guidance for the Years 2023, 2024 and 2025

ADMA Biologics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Co-Founder & Vice Chairman of the Board recently bought US$482k worth of stock

Executive VP recently sold US$973k worth of stock

Co-Founder notifies of intention to sell stock

Price target increased by 20% to US$6.00

ADMA Biologics, Inc. Updates Earnings Guidance for the Full Year 2023, 2024 and 2025

ADMA Biologics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

ADMA Biologics, Inc Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ADMA Biologics, Inc. Provides Financial Guidance for the Year 2023 and 2024-2025

ADMA Biologics, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

ADMA Biologics, Inc. Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA

Adma Biologics, Inc. Provides Earnings Guidance for the Full Year 2023

Price target increased to US$5.13

ADMA Biologics, Inc. Announces FDA Approval for Room Temperature Storage of Asceniv™ & Bivigam®

ADMA Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $59.999997 million.

ADMA Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $59.999997 million.

ADMA Biologics, Inc. Announces Revenue Guidance for the Quarter and Year Ending December 31, 2022

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Price target increased to US$5.00

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

ADMA Biologics, Inc. Revises Revenue Guidance for the Full Year 2022

No longer forecast to breakeven

ADMA Biologics, Inc. to Report Q3, 2022 Results on Nov 09, 2022

ADMA Biologics, Inc. Receives FDA Approval for Its Seventh Plasma Collection Center, Located in Greensboro, NC

No longer forecast to breakeven

ADMA Biologics: Strong Growth Is Clearing The Path To Profitability

Forecast to breakeven in 2024

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ADMA Biologics, Inc. Provides Earnings Guidance for the Fiscal Year 2022 and 2024

ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M

ADMA Biologics, Inc. to Report Q2, 2022 Results on Aug 10, 2022

ADMA Biologics, Inc. Receives FDA Approval for its Sixth Plasma Collection Center, Located in Myrtle Beach, SC

ADMA Biologics BioCenters Receives FDA Approval for its Sixth Plasma Collection Center, Located in Myrtle Beach, SC

ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

ADMA Biologics, Inc. Provides Revenue Guidance for the Remainder of 2022

ADMA Biologics: A Path To Profits Looks Clear

ADMA Biologics, Inc. Revises Earnings Guidance for the Year 2022

ADMA Biologics, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$5.83

ADMA: Pertinent Updates

Consensus forecasts updated

ADMA Biologics' 2021 Numbers Showed Continued Strong Execution

ADMA Biologics, Inc. to Report Q4, 2021 Results on Mar 24, 2022

ADMA Biologics, Inc. Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA